The Effect and Side Effect of Hydroxyurea Therapy on Patients With β-Thalassemia: A Systematic Review to December 2012

References

• Samavat A, Modell B. Iranian national thalassaemia screening program. BMJ. 2004;329(7475):1134–1137
   PubMed Web of Science ®Google Scholar
• Weatherall DJ, Clegg JB. The Thalassaemia Syndromes, 3rd ed. Oxford, UK: Blackwell Scientific Publications, 1981
   Google Scholar
• Aessopos A, Kati M, Melitis J. Thalassemia intermedia today: Should patients regulary receive transfusion? Transfusion. 2007;47(5):792–800
   PubMed Web of Science ®Google Scholar
• Lockamy VL, Huang J, Shields H, et al. Urease enhances the formation of iron nitrosyl hemoglobin in the presence of hydroxyurea. Biochim Biophys Acta. 2003;1622(2):109–116
   PubMedGoogle Scholar
• Buller MA, Elford LH, Dubios C, et al. A combination of hydroxyurea and isobutyramide to induce fetal hemoglobin in transgenic mice is more hematotoxic than the individual agents. Blood Cells Molec Dis. 1999;25(16):255–269
   PubMedGoogle Scholar
• Bradai M, Abad MT, Pissard S, et al. Hydroxyurea can eliminate transfusion requirements in children with severe β thalassemia. Blood. 2003;102(4):1529–1530
   PubMed Web of Science ®Google Scholar
• Deilami Khiabani Z, Banan M, Asgharian AM, et al. Efficacy of different dose of hydroxyurea on induction of γ-globin in K562 cells. Med J Islamic Azad Univ. 2009;19(3):147–153
   Google Scholar
• Lavelle D, Moloki R, Ducksworth J, Desimone J. Effect of hydroxyurea, stem cell factor, and erythropoitin in combination on fetal hemoglobin in the baboon. Exp Hematol. 2001;29(2):156–162
   PubMedGoogle Scholar
• Fathallah H, Sutton M, Atweh GF. Pharmacological induction of fetal hemoglobin: Why haven’t we been more successful in thalassemia? Ann N Y Acad Sci. 2005;1054:228–237
   PubMed Web of Science ®Google Scholar
• Rossig C, Freund G, Mayer G. Acute Leukemias VII Experimental Approaches and Novel Therapies. Berlin, Germany: Springer Verlag, 1998
   Google Scholar
• Platt O, Orkin S, Dover G, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest. 1984;74(2):652–656
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin ML, Moore RD, et al.; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;352(20):1317–1322
   Google Scholar
• Hajjar FM, Pearson HA. Pharmacologic treatment of thalassemia intermedia with hydroxyurea. J Pediatr. 1994;125(3):490–492
   PubMed Web of Science ®Google Scholar
• Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103(6):2039–2045
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C. Modern treatment of thalassaemia intermedia. Br J Haematol. 2007;138(3):291–304
   PubMed Web of Science ®Google Scholar
• Karimi M, Mohammadi F, Behmanesh F, et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with β-thalassemia intermedia. Eur J Haematol. 2009;84(1):52–58
   PubMedGoogle Scholar
• Rigano P, Pecoraro A, Calzolari R, et al. Desensitization to hydroxyurea following long-term treatment of thalassaemia intermedia as observed in vivo and primary erythroid cultures from treated patients. Br J Haematol. 2010;151(5):509–515
   PubMed Web of Science ®Google Scholar
• Yavarian M, Karimi M, Bakker E, et al. Response to hydroxyurea treatment in Iranian transfusion dependent β thalassemia patients. Haematologica. 2004;89(10):1172–1178
   PubMed Web of Science ®Google Scholar
• Ehsani MA, Hedayatiasl AA, Bagheri A. Effect of hydroxyurea in thalassemia intermedia patients. Behbood J. 2002;6(81):17–24
   Google Scholar
• Zamani F, Shakeri R, Eslami SM, et al. Hydroxyurea therapy in 49 patients with major β-thalassemia. Arch Iran Med. 2009;12(3):295–297
   PubMed Web of Science ®Google Scholar
• Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol/Oncol. 2005;27(7):380–385
   PubMed Web of Science ®Google Scholar
• Kosarian M, Yousefi G, Mahdavi M, et al. Effect of hydroxyurea in thalassemia intermedia. J MAZUMS. 2000;9(25):30–38
   Google Scholar
• Loukopoulos D, Voskaridou E, Kalotychou V, et al. Reduction of the clinical severity of sickle cell/β-thalassemia with hydroxyurea: The experience of a single center in Greece. Blood Cells Mol Dis. 2000;26(5):453–466
   PubMedGoogle Scholar
• Beliles R, Makris N, Scott W. Consideration of pharmacokinetics and temporal sensitivity for hydroxyurea in relation to teratogenic potential. Int J Toxicol. 1991;10(2):269–278
   Google Scholar
• Karimi M, Haghpanah S, Farhadi A, Yavarian M. Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. Int J Hematol. 2012;95(1):51–56
   PubMed Web of Science ®Google Scholar
• Hashemisoteh M, Akhavan-Niaki H, Kosaryan M, et al. The role of β gene mutations in response to hydroxyurea therapy in patients with β thalassemia patients. J MAZUMS. 2008;18(64):1–10
   Google Scholar
• Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med. 2008;358(13):1362–1369
   PubMed Web of Science ®Google Scholar
• Steinberg MH, Lu Z-H, Barton FB, et al. Fetal hemoglobin in sickle cell anemia: Determinants of response to hydroxyurea. Blood. 1997;89(3):1078–1088
   PubMed Web of Science ®Google Scholar
• Haynes J, Obiako B, Hester RB, et al. Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium. Am J Physiol-Heart Circ Physiol. 2008;294(1):H379–H85
   PubMed Web of Science ®Google Scholar
• Musallam K, Taher A, Cappellini M, Sankaran V. Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. Blood. 2013;121(12):2199–2212
   PubMed Web of Science ®Google Scholar
• Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001;323(7308):334–336
   PubMed Web of Science ®Google Scholar
• Pawson R, Greenhalgh T, Harvey G, Walshe K. Realist review – a new method of systematic review designed for complex policy interventions. J Health Serv Res Policy. 2005;10(Suppl 1):21–34
   PubMedGoogle Scholar
• McGann PT, Ware RE. Hydroxyurea for sickle cell anemia: What have we learned and what questions still remain? Curr Opin Hematol. 2011;18(3):158–165
   PubMed Web of Science ®Google Scholar
• Ware RE, Aygun B. Advances in the use of hydroxyurea. Hematology Am Soc Hematol Educ Program 2009:62–69
   PubMedGoogle Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996;17(1):1–12
   PubMedGoogle Scholar
• Mojtahedzadeh F, Kosaryan M, Kowsarian S, Karami H. Effect of hydroxyurea on extramedullary hematopoiesis masses in patients with β thalassemia intermedia. Pejohandeh. 2008;13(2):81–88
   Google Scholar
• Kosaryan M, Vahidshahi K, Karami H, Ehteshami S. Effect of hydroxyurea on thalassemia major and thalassemia intermedia in Iranian patients. Pak J Med Sci. 2009;25(1):74–78
   Web of Science ®Google Scholar
• Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z. Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. Iranian J Blood Cancer. 2009;1(4):147–150
   Google Scholar
• de Paula EV, Lima CS, Arruda VR, et al. Long-term hydroxyurea therapy in β-thalassaemia patients. Eur J Haematol. 2003;70(3):151–155
   PubMedGoogle Scholar
• Choudhry VP, Lal A, Pati HP, Arya LS. Hematological responses to hydroxyurea therapy in multitransfused thalassemic children. Indian J Pediatr. 1997;64(3):395–398
   PubMedGoogle Scholar
• Dixit A, Chatterjee TC, Mishra P, et al. Hydroxyurea in thalassemia intermedia – a promising therapy. Ann Hematol. 2005;84(7):441–446
   PubMed Web of Science ®Google Scholar
• Italia KY, Jijna FJ, Merchant R, et al. Response to hydroxyurea in β thalassemia major and intermedia: Experience in western India. Clin Chim Acta. 2009;407(1–2):10–15
   PubMed Web of Science ®Google Scholar
• Bradai M, Pissard S, Abad MT, et al. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. Transfusion. 2007;47(10):1830–1836
   PubMed Web of Science ®Google Scholar
• Kosaryan M, Karimi H, Zafari M, Yaghobi N. Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013. Hemoglobin. 2014;38(2):115–118
   PubMed Web of Science ®Google Scholar
• Koren A, Levin C, Dgany O, et al. Response to hydroxyurea therapy in β thalassemia. Am J Hematol. 2008;83(5):366–370
   PubMed Web of Science ®Google Scholar
• Cario H, Wegener M, Debating K-M. Treatment with hydroxyurea in thalassemia intermedia with paravertebra pseudo tumors of extra medullary hematopoiesis. Ann Hematol. 2002;81(8):478–482
   PubMed Web of Science ®Google Scholar
• Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P. Hydroxyurea in the treatment of major β-thalassemia and importance of genetic screening. Ann Hematol. 2004;83(7):430–433
   PubMed Web of Science ®Google Scholar
• Akbari MT, Izadyar M, Izadi P, Vardasbi S. Study of molecular basis of thalassemia intermedia and its relation to hematological indexes and clinical findings. Hakim Res J. 2000;3(4):298–307
   Google Scholar
• Najmabadi H, Neishabury M, Sahebjam F, et al. The Iranian Human Mutation Gene Bank: A data and sample resource for worldwide collaborative genetics research. Hum Mutat. 2003;21(2):146–150
   PubMedGoogle Scholar
• Jalali H, Mahdavi MR, Roshan P, et al. α Thalassemia gene mutations in neonates from Mazandaran, Iran, 2012. Hematology. 2013;19(4)192–195
   Google Scholar
• Karimi M. Hydroxyurea in the management of thalassemia intermedia. Hemoglobin. 2009;33(Suppl 1):S177–S182. 2013;19(4)192–195
   PubMedGoogle Scholar
• Banan M, Bayat H, Azarkeivan A, et al. The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients. Hemoglobin. 2012;36(4):371–380
   PubMed Web of Science ®Google Scholar
• Ehsani MA, Hedayati-Asl AA, Bagheri A, et al. Hydroxyurea-induced hematological response in transfusion-independent β-thalassemia intermedia: Case series and review of literature. Pediatr Hematol Oncol. 2009;26(8):560–565
   PubMed Web of Science ®Google Scholar
• Sami P. Hydroxyurea. Iran Generic Drug, 1st ed. Tehran, Iran: Nashr & Tabligh Bashari, 2013:615–616
   Google Scholar
• Zargari O, Kimyai Asadi A, Jafroodi M. Cutaneous adverse reactions to hydroxyurea in patients with intermedia thalassemia. Pediatr Dermatol. 2004;21(6):633–635
   PubMed Web of Science ®Google Scholar
• Amoozgar H, Farhani N, Karimi M. Risk factors for pulmonary hypertension in patients with thalassemia intermedia. Eur J Haematol. 2011;85(6):549–551
   Google Scholar
• Amoozgar H, Farhani N, Karimi M. Early echocardiographic findings in β thalassemia intermedia patients using standard and tissue doppler methods. Pediatr Cardiol. 2011;32(2):154–159
   PubMed Web of Science ®Google Scholar
• Karimi M, Cohan N, Moosavizadeh K, et al. Adverse effect of hydroxyurea in β thalassemia intermedia patients: 10 years experience. Pediatr Hematol Oncol. 2010;27(3):205–211
   PubMed Web of Science ®Google Scholar
• Rashidighader F, Kosaryan M, Farzin D. High-dose deferoxamine treatment (intravenous) for thalassemia patients with cardiac complications. East Mediterr Health J. 2007;13(5):1053–1059
   PubMedGoogle Scholar
• Triadou P, Maier-Redelsperger M, Krishnamoorty R, et al. Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease. Nouv Rev Fr Hematol. 1994;36(5):367–372
   PubMedGoogle Scholar
• Karimi M, Zekavat O, Haghpanah S, et al. Comparative study of hypogonadism in β-thalassemia intermedia patients with and without hydroxyurea. Hematology. 2012;17(2):122–124
   PubMed Web of Science ®Google Scholar
• Singer ST, Kuypers FA, Olivieri NF, et al. Single and combination drug therapy for fetal hemoglobin augmentation in Hemoglobin E-β0-thalassemia: Consideration for treatment. Ann N Y Acad Sci. 2005;1054:250–256
   PubMed Web of Science ®Google Scholar
• Yates A, Dedeken L, Smeltzer M, et al. Hydroxyurea treatment of children with Hemoglobin SC disease. Pediatr Blood Cancer. 2012;60(2):323–325
   PubMedGoogle Scholar
• Fathallah H, Atweh GF. Induction of fetal hemoglobin in the treatment of sickle cell disease. Hematology Am Hematol Soc Educ Program. 2006:58–62
   Google Scholar